Mease PJ, Chohan S, Garcia Fructuoso FJ, Gottlieb AB, Chou RC, Mendelsohn AM, Luggen ME. Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis. J of Skin [Internet]. 2020Sep.2 [cited 2024Jul.22];4(5):s43. Available from: https://jofskin.org/index.php/skin/article/view/992